Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012-2015.
Recent trends in the prevalence of low-dose aspirin use for primary and secondary prevention of cardiovascular disease in the United States, 2012-2015.
复制标题
DOI：
10.1016/j.pmedr.2016.12.023
复制
发表时间：
2017-03
影响因子：
2.8
通讯作者：
Bernstein, Brent
中科院分区：
文献类型：
--
作者：
Stuntz, Mark;Bernstein, Brent
阿司匹林治疗已被证明是一种有效的预防措施，可降低新发或复发心血管事件的风险。这项研究的目的是提供2012年至2015年期间低剂量阿司匹林用于一级和二级CVD预防的流行病学分析。自我报告的低剂量阿司匹林用于一级和二级CVD预防的估计值来自2012-2015年的国家健康访谈调查。使用logistic回归分析评估阿司匹林用于一级和二级CVD预防的患病率的时间变化。在2012-2015年期间，23.3%的受访者自我报告服用阿司匹林作为CVD的一级预防，从2012年的23.7%下降到2015年的21.8%。在此期间，8.4%的人自称服用阿司匹林进行二级心血管疾病预防，从2012年的8.9%下降到2015年的8.2%。总体而言，阿司匹林用于预防CVD的流行率从2012年的32.6%下降到2015年的30.0%。这项研究表明，超过30%的成年人自我报告服用低剂量阿司匹林用于一级或二级CVD预防。尽管在过去的四年中，这种患病率有所下降，但阿司匹林治疗仍然是预防CVD的一种高度利用的手段。超过30%的40岁以上的成年人服用阿司匹林来预防心血管疾病。非西班牙裔黑人中阿司匹林用于一级心血管疾病预防的比例增加。阿司匹林用于CVD一级和二级预防的总体流行率下降
Aspirin therapy has been shown to be an effective prevention measure to reduce the risk of new or recurring cardiovascular events. The aim of this study was to provide an epidemiological analysis of low-dose aspirin use for primary and secondary CVD prevention from 2012 to 2015. Estimates of self-reported low-dose aspirin use for primary and secondary CVD prevention were obtained from the National Health Interview Survey for the years 2012–2015. Temporal changes in the prevalence of aspirin use for primary and secondary CVD prevention were assessed using logistic regression. During 2012–2015, 23.3% of respondents self-reported as taking aspirin for primary CVD prevention, decreasing from 23.7% in 2012 to 21.8% in 2015. Also during this period, 8.4% self-reported as taking aspirin for secondary CVD prevention, decreasing from 8.9% in 2012 to 8.2% in 2015. Overall, the prevalence of aspirin use for CVD prevention declined from 32.6% in 2012 to 30.0% in 2015. This study shows that over 30% of the adult population self-reports as taking low-dose aspirin for primary or secondary CVD prevention. Despite the decline in this prevalence over the previous four years, aspirin therapy remains a highly-utilized means of preventing CVD. Over 30% of adults aged ≥ 40 years take aspirin to prevent cardiovascular disease. Aspirin use for primary CVD prevention increased among non-Hispanic blacks. Overall prevalence of aspirin for both primary and secondary CVD prevention declined